NZ Pharmac saves, but says no to imatinib mesylate

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.374, 2002-01, pp. : 12-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

NZ Pharmac funds new treatments

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 628, 2011-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Imatinib mesylate promising for CML

By  

Inpharma, Vol. 1, Iss. 1303, 2001-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

A validated LC method for imatinib mesylate

By Vivekanand V.V.   Sreenivas Rao D.   Vaidyanathan G.   Sekhar N.M.   Avijit Kelkar S.   Ramachandra Puranik P.  

Journal of Pharmaceutical and Biomedical Analysis, Vol. 33, Iss. 5, 2003-12 ,pp. : 879-889

Elsevier

Access to resources Recommend Favorite

Imatinib Mesylate: A Viewpoint by Ian Judson

By Judson I.  

Drugs, Vol. 63, Iss. 5, 2003-01 ,pp. : 523-524

Adis International

Access to resources Recommend Favorite

Imatinib mesylate: response in hypereosinophilic syndrome

By  

Inpharma, Vol. 1, Iss. 1381, 2003-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite